The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the ...

The goal of Advanced Oncotherapy (LON:AVO) is to deliver an affordable and more effective proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In ...

Advanced Oncotherapy (LON:AVO) is the topic of conversation when Hardman and Co’s Head of Life Sciences Dr Martin Hall caught up with DirectorsTalk for an exclusive interview. Q1: You recently ...

Advanced Oncotherapy plc (LON: AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting ...

Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by achievement ...

Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton beam therapy system (PBT), based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by ...

Advanced Oncotherapy (LON:AVO)  goal is to deliver an affordable and novel proton therapy (PT) system, based on state-of-the-art technology developed originally at the CERN. Achievement of major technical milestones has ...

Advanced Oncotherapy (LON:AVO)  goal is to deliver an affordable and novel proton therapy system (PT), based on state-of-the-art technology developed originally at the world-renowned CERN. Achievement of major technical milestones ...

Advanced Oncotherapy Plc (LON:AVO), the developer of next generation proton therapy systems for cancer treatment, announced today its audited results for the year ended 31 December 2017, another year of ...

Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that the Company has received £10 million from Yantai Cipu, through its affiliated entity ...